Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia

Daniel Herranz, Alberto Ambesi-Impiombato, Jessica Sudderth, Marta Sánchez-Martín, Laura Belver, Valeria Tosello, Luyao Xu, Agnieszka A. Wendorff, Mireia Castillo, J. Erika Haydu, Javier Márquez, José M. Matés, Andrew L. Kung, Stephen Rayport, Carlos Cordon-Cardo, Ralph J. Deberardinis, Adolfo A. Ferrando

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Activating mutations in NOTCH1 are common in T cell acute lymphoblastic leukemia (T-ALL). Here we identify glutaminolysis as a critical pathway for leukemia cell growth downstream of NOTCH1 and a key determinant of the response to anti-NOTCH1 therapies in vivo. Mechanistically, inhibition of NOTCH1 signaling in T-ALL induces a metabolic shutdown, with prominent inhibition of glutaminolysis and triggers autophagy as a salvage pathway supporting leukemia cell metabolism. Consequently, inhibition of glutaminolysis and inhibition of autophagy strongly and synergistically enhance the antileukemic effects of anti-NOTCH1 therapy in mice harboring T-ALL. Moreover, we demonstrate that Pten loss upregulates glycolysis and consequently rescues leukemic cell metabolism, thereby abrogating the antileukemic effects of NOTCH1 inhibition. Overall, these results identify glutaminolysis as a major node in cancer metabolism controlled by NOTCH1 and as therapeutic target for the treatment of T-ALL.

Original languageEnglish (US)
Pages (from-to)1182-1189
Number of pages8
JournalNature Medicine
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
T-cells
Metabolism
Enzyme inhibition
Autophagy
Leukemia
Salvaging
Critical Pathways
Cell growth
Glycolysis
Therapeutics
Up-Regulation
Mutation
Growth
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Herranz, D., Ambesi-Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., ... Ferrando, A. A. (2015). Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 21(10), 1182-1189. https://doi.org/10.1038/nm.3955

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. / Herranz, Daniel; Ambesi-Impiombato, Alberto; Sudderth, Jessica; Sánchez-Martín, Marta; Belver, Laura; Tosello, Valeria; Xu, Luyao; Wendorff, Agnieszka A.; Castillo, Mireia; Haydu, J. Erika; Márquez, Javier; Matés, José M.; Kung, Andrew L.; Rayport, Stephen; Cordon-Cardo, Carlos; Deberardinis, Ralph J.; Ferrando, Adolfo A.

In: Nature Medicine, Vol. 21, No. 10, 01.10.2015, p. 1182-1189.

Research output: Contribution to journalArticle

Herranz, D, Ambesi-Impiombato, A, Sudderth, J, Sánchez-Martín, M, Belver, L, Tosello, V, Xu, L, Wendorff, AA, Castillo, M, Haydu, JE, Márquez, J, Matés, JM, Kung, AL, Rayport, S, Cordon-Cardo, C, Deberardinis, RJ & Ferrando, AA 2015, 'Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia', Nature Medicine, vol. 21, no. 10, pp. 1182-1189. https://doi.org/10.1038/nm.3955
Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine. 2015 Oct 1;21(10):1182-1189. https://doi.org/10.1038/nm.3955
Herranz, Daniel ; Ambesi-Impiombato, Alberto ; Sudderth, Jessica ; Sánchez-Martín, Marta ; Belver, Laura ; Tosello, Valeria ; Xu, Luyao ; Wendorff, Agnieszka A. ; Castillo, Mireia ; Haydu, J. Erika ; Márquez, Javier ; Matés, José M. ; Kung, Andrew L. ; Rayport, Stephen ; Cordon-Cardo, Carlos ; Deberardinis, Ralph J. ; Ferrando, Adolfo A. / Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. In: Nature Medicine. 2015 ; Vol. 21, No. 10. pp. 1182-1189.
@article{09f96360373e49dc8db2a5e5d35ca8cd,
title = "Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia",
abstract = "Activating mutations in NOTCH1 are common in T cell acute lymphoblastic leukemia (T-ALL). Here we identify glutaminolysis as a critical pathway for leukemia cell growth downstream of NOTCH1 and a key determinant of the response to anti-NOTCH1 therapies in vivo. Mechanistically, inhibition of NOTCH1 signaling in T-ALL induces a metabolic shutdown, with prominent inhibition of glutaminolysis and triggers autophagy as a salvage pathway supporting leukemia cell metabolism. Consequently, inhibition of glutaminolysis and inhibition of autophagy strongly and synergistically enhance the antileukemic effects of anti-NOTCH1 therapy in mice harboring T-ALL. Moreover, we demonstrate that Pten loss upregulates glycolysis and consequently rescues leukemic cell metabolism, thereby abrogating the antileukemic effects of NOTCH1 inhibition. Overall, these results identify glutaminolysis as a major node in cancer metabolism controlled by NOTCH1 and as therapeutic target for the treatment of T-ALL.",
author = "Daniel Herranz and Alberto Ambesi-Impiombato and Jessica Sudderth and Marta S{\'a}nchez-Mart{\'i}n and Laura Belver and Valeria Tosello and Luyao Xu and Wendorff, {Agnieszka A.} and Mireia Castillo and Haydu, {J. Erika} and Javier M{\'a}rquez and Mat{\'e}s, {Jos{\'e} M.} and Kung, {Andrew L.} and Stephen Rayport and Carlos Cordon-Cardo and Deberardinis, {Ralph J.} and Ferrando, {Adolfo A.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1038/nm.3955",
language = "English (US)",
volume = "21",
pages = "1182--1189",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia

AU - Herranz, Daniel

AU - Ambesi-Impiombato, Alberto

AU - Sudderth, Jessica

AU - Sánchez-Martín, Marta

AU - Belver, Laura

AU - Tosello, Valeria

AU - Xu, Luyao

AU - Wendorff, Agnieszka A.

AU - Castillo, Mireia

AU - Haydu, J. Erika

AU - Márquez, Javier

AU - Matés, José M.

AU - Kung, Andrew L.

AU - Rayport, Stephen

AU - Cordon-Cardo, Carlos

AU - Deberardinis, Ralph J.

AU - Ferrando, Adolfo A.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Activating mutations in NOTCH1 are common in T cell acute lymphoblastic leukemia (T-ALL). Here we identify glutaminolysis as a critical pathway for leukemia cell growth downstream of NOTCH1 and a key determinant of the response to anti-NOTCH1 therapies in vivo. Mechanistically, inhibition of NOTCH1 signaling in T-ALL induces a metabolic shutdown, with prominent inhibition of glutaminolysis and triggers autophagy as a salvage pathway supporting leukemia cell metabolism. Consequently, inhibition of glutaminolysis and inhibition of autophagy strongly and synergistically enhance the antileukemic effects of anti-NOTCH1 therapy in mice harboring T-ALL. Moreover, we demonstrate that Pten loss upregulates glycolysis and consequently rescues leukemic cell metabolism, thereby abrogating the antileukemic effects of NOTCH1 inhibition. Overall, these results identify glutaminolysis as a major node in cancer metabolism controlled by NOTCH1 and as therapeutic target for the treatment of T-ALL.

AB - Activating mutations in NOTCH1 are common in T cell acute lymphoblastic leukemia (T-ALL). Here we identify glutaminolysis as a critical pathway for leukemia cell growth downstream of NOTCH1 and a key determinant of the response to anti-NOTCH1 therapies in vivo. Mechanistically, inhibition of NOTCH1 signaling in T-ALL induces a metabolic shutdown, with prominent inhibition of glutaminolysis and triggers autophagy as a salvage pathway supporting leukemia cell metabolism. Consequently, inhibition of glutaminolysis and inhibition of autophagy strongly and synergistically enhance the antileukemic effects of anti-NOTCH1 therapy in mice harboring T-ALL. Moreover, we demonstrate that Pten loss upregulates glycolysis and consequently rescues leukemic cell metabolism, thereby abrogating the antileukemic effects of NOTCH1 inhibition. Overall, these results identify glutaminolysis as a major node in cancer metabolism controlled by NOTCH1 and as therapeutic target for the treatment of T-ALL.

UR - http://www.scopus.com/inward/record.url?scp=84944076036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944076036&partnerID=8YFLogxK

U2 - 10.1038/nm.3955

DO - 10.1038/nm.3955

M3 - Article

VL - 21

SP - 1182

EP - 1189

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -